KEGG   DRUG: Yttrium Y 90 epratuzumab tetraxetan
Entry
D06349                      Drug                                   
Name
Yttrium Y 90 epratuzumab tetraxetan (USAN)
Efficacy
Antineoplastic, Radioactive agent, Anti-CD22 antibody
Comment
Antibody-drug conjugate
Radioimmunotherapy (RAIT) for non-Hodgkin's B-cell lymphoma
Target
CD22 (SIGLEC2) [HSA:933] [KO:K06467]
  Pathway
hsa04514  Cell adhesion molecules
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   SIGLEC family
    CD22 (SIGLEC2)
     D06349  Yttrium Y 90 epratuzumab tetraxetan (USAN)
Other DBs
CAS: 501423-25-2
PubChem: 47208006
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system